Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study.

Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study.

Thorax (2021-02-27)

Andrew J Swift, Frederick Wilson, Marcella Cogliano, Lindsay Kendall, Faisal Alandejani, Samer Alabed, Paul Hughes, Yousef Shahin, Laura Saunders, Charlotte Oram, David Capener, Alex Rothman, Pankaj Garg, Christopher Johns, Matthew Austin, Alistair Macdonald, Jo Pickworth, Peter Hickey, Robin Condliffe, Anthony Cahn, Allan Lawrie, Jim M Wild, David G Kiely

PMID33632769

ABSTRACT

End points that are repeatable and sensitive to change are important in pulmonary arterial hypertension (PAH) for clinical practice and trials of new therapies. In 42 patients with PAH, test-retest repeatability was assessed using the intraclass correlation coefficient and treatment effect size using Cohen's d statistic. Intraclass correlation coefficients demonstrated excellent repeatability for MRI, 6 min walk test and log to base 10 N-terminal pro-brain natriuretic peptide (log10NT-proBNP). The treatment effect size for MRI-derived right ventricular ejection fraction was large (Cohen's d 0.81), whereas the effect size for the 6 min walk test (Cohen's d 0.22) and log10NT-proBNP (Cohen's d 0.20) were fair. This study supports further evaluation of MRI as a non-invasive end point for clinical assessment and PAH therapy trials.Trial registration number NCT03841344.

MATERIALS

Product Number

Brand

Product Description

HCVD1MAG-67K

Millipore

MILLIPLEX^® Human Cardiovascular Disease (CVD) Magnetic Bead Panel 1 - Cardiovascular Disease Multiplex Assay, The analytes available for this multiplex kit are: BNP, NT-proBNP, CK-MB, CXCL6/GCP-2, CXCL16, Endocan-1 (ESM-1), FABP3, FABP4, LIGHT, Oncostatin (OSM), Placental Growth Factor (PlGF), Troponin I (TnI).